• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Antibody profiling and prevalence in US patients during the SARS-CoV2 pandemic

tetano

Editor, Senior Moderator
PLoS One


. 2020 Nov 19;15(11):e0242655.
doi: 10.1371/journal.pone.0242655. eCollection 2020.
Antibody profiling and prevalence in US patients during the SARS-CoV2 pandemic


Hari Krishnan Krishnamurthy[SUP] 1 [/SUP], Vasanth Jayaraman[SUP] 1 [/SUP], Karthik Krishna[SUP] 1 [/SUP], Karenah E Rajasekaran[SUP] 2 [/SUP], Tianhao Wang[SUP] 1 [/SUP], Kang Bei[SUP] 1 [/SUP], John J Rajasekaran[SUP] 1 [/SUP], Inna Yaskin[SUP] 3 [/SUP], Alex J Rai[SUP] 4 [/SUP], Rok Seon Choung[SUP] 5 [/SUP], Joseph A Murray[SUP] 5 [/SUP]



Affiliations

Abstract

Background: Antibody diagnostics play an important role in disease detection and can potentially aid in monitoring of the immune responses to see if an individual has developed immunity. Developing high throughput diagnostics which does not involve handling of infectious material becomes imperative in the case of pandemics such as the recent outbreak of SARS-CoV2.
Methods: A protein microarray technology was used to detect the plurality of antibody response to four novel antigens namely S1 glycoprotein, Receptor binding domain (RBD), S2 glycoprotein and Nucleoprotein of the novel coronavirus named SARS-CoV2 using serum samples. A DBS card was additionally used to compare its performance with a venipuncture-based serum separator tube (SST) draw.
Results: The three main subclasses of antibodies IgM, IgA and IgG were analyzed to see the variations in immune responses in the affected population and compared to their microbial RT-PCR based NP swab results. The clinical sensitivity and specificity were determined to be 99.67% and 99.77%. In the matrix comparison study, which would enable patients to test without risk of transmitting the virus, DBS (Dried Blood Spot) matched with higher than 98% accuracy to a venipuncture-based SST collection.
Conclusion: Multiplex testing enables higher sensitivity and specificity which is essential while establishing exposure on a population scale. This flexible platform along with a discrete collection methodology would be crucial and broadly useful to scale up testing in current and future pandemics. Minimum sample volume that can be collected using DBS cards can be processed in this multiplex pillar plate format enabling the capacity to provide the reliability of high throughput analyzers while having the ease of collection similar to rapid tests.
 
Back
Top Bottom